AptaBio Therapeutics Past Earnings Performance
Past criteria checks 0/6
AptaBio Therapeutics's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 10.8% annually. Revenues have been growing at an average rate of 569.8% per year.
Key information
-12.3%
Earnings growth rate
-12.3%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 569.8% |
| Return on equity | -19.7% |
| Net Margin | -3,664.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How AptaBio Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 324 | -11,867 | 3,915 | 12,380 |
| 30 Sep 23 | 53 | -13,289 | 3,626 | 9,240 |
| 31 Dec 22 | 48 | -10,565 | 2,788 | 6,197 |
Quality Earnings: A293780 is currently unprofitable.
Growing Profit Margin: A293780 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A293780's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A293780's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A293780 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A293780 has a negative Return on Equity (-19.66%), as it is currently unprofitable.